| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
IDE1 (Inducer of definitive endoderm 1) is a novel, potent and cell-permeable inducer of definitive endoderm formation with EC50 of 125 nM). IDE1 induces Sox17 expression. It also activates TGF-β signaling and downstream Smad2 phosphorylation. IDE1 upregulates Nodal expression. It induces differentiation of mouse or human pluripotent stem cells (PSCs) by activating SMAD2 phosphorylation and NODAL expression (Borowiak et al.). At EC₅₀ = 125 nM, SOX17 expression was induced in mouse ES cells.
| ln Vitro |
Human induced pluripotent stem cells (hiPSCs) secrete more definitive endoderm (DE) when IDE1 is present. In 2D and 3D cultures, activin A/Wnt3a was found to be substantially more potent than IDE1. IDE1 can effectively induce DE by a variety of in vitro procedures. When IDE-1 was used to treat hiPSC-derived EBs, there was a somewhat higher number of DE-labeled cells than when Activin A/Wnt3a was used (p<0.01). IDE1 is superior to other inducers in a number of ways, including high permeability, influence, diversity, and user-friendliness. Melton's group demonstrated for the first time that two tiny molecules, IDE1 and IDE2, that are permeable to cells, can take the place of activin A. In the sidewall, IDE1 can cause Smad2 phosphorylation at least 24 hours later and at amounts similar to those brought on by activin A therapy. While endoderm rupture is caused by IDE1 (2 mM) treatment of hiPSCs, the efficiency is much lower than that of Activin A/Wnt3a[1].
|
|---|---|
| References |
| Molecular Formula |
C15H18N2O5
|
|---|---|
| Molecular Weight |
306.313824176788
|
| Exact Mass |
306.121
|
| CAS # |
1160927-48-9
|
| PubChem CID |
23749403
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.572
|
| LogP |
1.66
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
22
|
| Complexity |
422
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C(=C1)/C=N/NC(=O)CCCCCC(=O)O)C(=O)O
|
| InChi Key |
ABKJCDILEUEJSH-MHWRWJLKSA-N
|
| InChi Code |
InChI=1S/C15H18N2O5/c18-13(8-2-1-3-9-14(19)20)17-16-10-11-6-4-5-7-12(11)15(21)22/h4-7,10H,1-3,8-9H2,(H,17,18)(H,19,20)(H,21,22)/b16-10+
|
| Chemical Name |
7-[2-(2-Carboxybenzylidene)hydrazinyl]-7-oxoheptanoic acid
|
| Synonyms |
IDE1 IDE-1 IDE 1.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 30 mg/mL (~97.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2647 mL | 16.3233 mL | 32.6467 mL | |
| 5 mM | 0.6529 mL | 3.2647 mL | 6.5293 mL | |
| 10 mM | 0.3265 mL | 1.6323 mL | 3.2647 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA